The move rebrands the respiratory services acquired by iCardiac and reflects enhanced capabilities
March 22, 2016, Rochester, NY - iCardiac Technologies, Inc., a market leader in the conduct of respiratory and cardiac safety studies, today unveiled “PFT Global”, the new name of its respiratory testing service line. The move completes a six-month process of integrating the clinical trials division of nSpire Health, which was acquired in July 2015, into the iCardiac organization. It also reflects the broader respiratory service capabilities that were enabled by the acquisition.
The newly named PFT Global service line continues to be a leader in respiratory clinical research, having captured over 10 million pulmonary function tests worldwide over the past 10 years and supporting research sites in over 60 countries. The business is focused on supporting clinical trials in Phase II and III. This includes study sizes ranging from two sites and 50 patients to global-scale pivotal projects covering 30 countries with 750 clinical sites and 14,000 subjects.
“This renaming was the culmination of our comprehensive efforts to integrate our acquired respiratory services into iCardiac,” said John Sage, Senior Vice President of Respiratory and ePRO at iCardiac. “As a result of the integration, our sponsors will benefit from various enhanced capabilities, including our broader capacity and resources in relation to project management, site support, and global logistics.”
“This new name of our respiratory service line represents a company milestone and symbolizes what we offer to sponsors,” said Alex Zapesochny, President and CEO of iCardiac. “Over the years we have become a company with superb global capabilities, and we offer an expertise in pulmonary function testing that is second to none.”
About iCardiac Technologies:
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for respiratory and cardiac safety services. Its high precision cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit: www.icardiac.com.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.